Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... MSD says Keytruda is the first anti-PD-1 drug to improve

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care. Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new ... The JAVELIN Renal 101 study reported at this week’s ESMO conference paired

Cancer disruptor F Star names next CEO

F-star has two assets in development, including its lead first-in-class, Merck KGaA-partnered candidate FS118, which works by simultaneously blocking two tumour growth promoting immune checkpoint molecules. ... The company has deals with the likes of

A look ahead to key trial readouts at ESMO

In immuno-oncology, this year’s offering includes a first showing for data in first-line advanced renal cell carcinoma for Merck KGaA/Pfizer’s Bavencio (avelumab) in the JAVELIN Renal ... Merck &Co/MSD – already dominating non-small cell lung

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]